Laura Vallejo Torres-rekin lankidetzan egindako argitalpenak (10)

2022

  1. Are Estimates of the Health Opportunity Cost Being Used to Draw Conclusions in Published Cost-Effectiveness Analyses? A Scoping Review in Four Countries

    Applied Health Economics and Health Policy, Vol. 20, Núm. 3, pp. 337-349

2021

  1. Métodos para la evaluación económica de programas de cribado neonatal

    Revista espanola de salud publica, Vol. 95

2018

  1. Cost-effectiveness analysis of real-time continuous monitoring glucose compared to self-monitoring of blood glucose for diabetes mellitus in Spain

    Journal of Evaluation in Clinical Practice, Vol. 24, Núm. 4, pp. 772-781

2017

  1. Cost-effectiveness methods and newborn screening assessment

    Advances in Experimental Medicine and Biology (Springer New York LLC), pp. 267-281

2016

  1. Cost-effectiveness analysis of newborn screening for sickle-cell disease in Spain

    Expert Opinion on Orphan Drugs, Vol. 4, Núm. 6, pp. 567-575

  2. On the Estimation of the Cost-Effectiveness Threshold: Why, What, How?

    Value in Health, Vol. 19, Núm. 5, pp. 558-566

2015

  1. Cost-effectiveness analysis of a national newborn screening program for biotinidase deficiency

    Pediatrics, Vol. 136, Núm. 2, pp. e424-e432

  2. Cost-effectiveness of electroconvulsive therapy compared to repetitive transcranial magnetic stimulation for treatment-resistant severe depression: A decision model

    Psychological Medicine, Vol. 45, Núm. 7, pp. 1459-1470

  3. Effectiveness and cost-effectiveness of knowledge transfer and behavior modification interventions in type 2 diabetes mellitus patients-the INDICA study: A cluster randomized controlled trial

    Implementation Science, Vol. 10, Núm. 1

  4. Neonatal screening in Spain and cost-effectiveness

    Expert Opinion on Orphan Drugs, Vol. 3, Núm. 9, pp. 971-974